GUTS Stock Analysis: Buy, Sell, or Hold?
GUTS - Fractyl Health, Inc. Common Stock
$0.45
-0.02 (-5.27%)
▼
5d:
-78.9%
30d:
-80.12%
90d:
-63.63%
WAIT
LOW Confidence
Last Updated: February 3, 2026
Earnings: Mar 02, 2026
26d
Get Alerted When GUTS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
16 traders called GUTS this week
72% bullish • 8 bearish
72% bullish • 8 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: GUTS is down 78.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: GUTS is down 78.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: GUTS is currently trading at $0.45, which is considered oversold relative to its 30-day fair value range of $1.24 to $2.41.
Technical Outlook: Technically, GUTS is in a downtrend. Immediate support is located at $0.43, while resistance sits at $2.30. Short-term momentum is weak, with the stock down 5.3% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $5.24 (+1071.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, GUTS is in a downtrend. Immediate support is located at $0.43, while resistance sits at $2.30. Short-term momentum is weak, with the stock down 5.3% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $5.24 (+1071.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$1.24 -
$2.41
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.3%)
- BULLISH: Trading 1071.2% below Wall St target ($5.24)
- WARNING: Recommendation downgraded due to -78.9% 5-day decline - wait for stabilization
Fair Price Analysis
30-Day Fair Range
$1.24 -
$2.41
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$0.43
Resistance Level
$2.30
Current Trend
Downtrend
Fundamental Context
Forward P/E (Next Year Est.)
-0.65
Wall Street Target
$5.24
(+1071.2%)
Revenue Growth (YoY)
-57.1%
Last updated: February 03, 2026 4:06 PM ET
Data refreshes hourly during market hours. Next update: 5:06 PM
Data refreshes hourly during market hours. Next update: 5:06 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GUTS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 67 BUY |
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 56 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$85 | 53 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$117 | 61 BUY |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$140 | 50 HOLD |
